Aprea Therapeutics (APRE)
(Real Time Quote from BATS)
$3.34 USD
+0.12 (3.73%)
Updated Aug 13, 2024 01:24 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
APRE 3.34 +0.12(3.73%)
Will APRE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APRE
Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Lags Revenue Estimates
APRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now
Other News for APRE
Buy Rating Justified by Aprea Therapeutics’ Financial Health and Innovative Clinical Trials
Wedbush Initiates a Buy Rating on Aprea Therapeutics (APRE)
APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024
Analysts Are Bullish on These Healthcare Stocks: Aprea Therapeutics (APRE), TScan Therapeutics (TCRX)
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update